Search 90 products by drug, renal measure or dialysis term. Each result identifies the formulation, the label used and the limits of its renal guidance.
For severe renal impairment, start at 200 mg once daily on the prescribed treatment days. Mild or moderate impairment does not require renal adjustment.
Limits and monitoring
Retain the indication-specific treatment cycle, ECG and electrolyte monitoring. Do not interpret a daily dose as continuous 28-day administration.
The inequality in the U.S. renal subsection is awkwardly rendered. Verify the named severity category in the label. eviQ provides a separate indexed-eGFR instruction for its metastatic breast cancer regimen.
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Renal action or finding
At CrCl 30-50 mL/min there is no renal adjustment. With ESRD on regular HD, start at 2 mg once daily and limit the total to 18 mg/day. A post-HD supplement is unnecessary.
Limits and monitoring
Severe renal impairment without regular dialysis was not studied. Verify XL and Parkinson disease indication.
Initiation at eGFR 30-45 is not recommended. If eGFR falls below 45 during use, reassess benefit and risk and limit sitagliptin to 50 mg once daily. Below 30, discontinue; use is contraindicated.
Limits and monitoring
Check component strengths and metformin precautions around iodinated contrast.
For heart failure, at eGFR 30-50 consider starting at 25 mg every other day because of hyperkalemia risk. At eGFR >50 and potassium <=5 mEq/L, the initial dose is 25 mg daily.
Limits and monitoring
Check potassium within one week of starting or titrating and regularly thereafter. Verify baseline potassium, volume status and interacting drugs.
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Renal action or finding
For as-needed ED at CrCl 30-50 mL/min, start with 5 mg up to once daily; 10 mg is limited to once every 48 hours. Below 30 or on HD, do not exceed 5 mg every 72 hours.
Limits and monitoring
Select the intended schedule and indication first. Once-daily ED/BPH and pulmonary hypertension have different instructions.
Clinical renal category or population named in the cited section
Renal action or finding
No renal dose adjustment is recommended; studied exposure included patients with ESRD.
Limits and monitoring
During initiation or escalation, check renal function if significant GI adverse effects cause or could cause volume depletion. Confirm the prescribed brand.
